Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.64 |
| ▸ | CNR1 | P21554 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892861 | 0.87 | CNR2 (0.66) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL9892028 | 0.85 | CNR2 (0.74) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL2575204 | 0.85 | CNR2 (0.74) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL9893184 | 0.85 | CNR2 (0.74) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL9892039 | 0.84 | CNR2 (0.67) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892848 | 0.79 | CNR2 (0.60) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL20458273 | 0.79 | CNR2 (0.60) | CNR2CNR1SMN1; SMN2CYP2C8CYP2C9 | |
| SCHEMBL9892040 | 0.78 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL3707377 | 0.77 | SMN1; SMN2 (0.64) | CNR2CNR1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL9103651 | 0.77 | SMN1; SMN2 (0.64) | CNR2CNR1SMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885SMN1; SMN2 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.